KAZIA THERAPEUTICS

A company developing innovative, high-impact drugs for cancer

Presentation to Switzer Small & Microcap Conference 2019

Dr James Garner
Chief Executive Officer

Sydney, Australia 3 December 2019

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Investment Rationale

1. Our lead program, GDC-0084, was **designed by Genentech**, and is being developed for glioblastoma, the most common form of brain cancer, where the only available drug is ineffective for two-thirds of patients

2. GDC-0084 has shown strong evidence of efficacy in an ongoing phase II human trial in the United States; a pivotal study for registration is planned to commence in CY 2020

3. **Four other clinical trials** of GDC-0084 are currently underway at leading US hospitals, all primarily funded by external parties, covering a broad range of primary and secondary brain cancers to provide **multiple shots on goal**

4. Company is **well-financed**, following a recent institutional placement, with multiple value-driving data read-outs expected during the early part of CY 2020 and high potential to partner with big pharma

Six ongoing clinical trials across two assets, lead program covers full range of brain cancers

GDC-0084

Primary Brain Cancer
(brain cancer that begins in the brain)

Glioblastoma
Most common and most aggressive brain tumour

Phase II

NCT03522298

KAZIA THERAPEUTICS

DIPG
Highly aggressive childhood brain tumour

Phase I

NCT03696355

St. Jude Children's Research Hospital
ALSAC • Danny Thomas, Founder

Secondary Brain Cancer
(brain cancer that spreads from elsewhere in the body)

Brain Metastases
Cancer that has spread from any primary tumour

Phase II

NCT03994796

NIH NATIONAL CANCER INSTITUTE

Breast Cancer Brain Mets
(combination with Herceptin®)

Phase II

NCT03765983

DANA-FARBER CANCER INSTITUTE

Brain Metastases
(combination with radiotherapy)

Phase I

Memorial Sloan Kettering Cancer Center

Cantrixil

Ovarian Cancer

Platinum-Resistant Ovarian Ca.
(combination with chemotherapy)

Phase I

NCT02903771

KAZIA THERAPEUTICS

Funded by Kazia

Funded Primarily Through Partnerships and External Funding

Funded by Kazia

Kazia has delivered all milestones to date, with multiple data read-outs expected over 6-12 months



Note: forward-looking milestones are forecast and indicative but subject to revision

Treatment of brain cancer has improved little in recent decades, unlike other cancers



KAZIA THERAPEUTICS

Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer



Glioblastoma Multiforme

133,000 cases per annum worldwide

Indicative Market Opportunity

US$ 1.5 billion

No clear cause

or strong risk factors

3-4 months

untreated survival

12-15 months

average survival with treatment

Any age, but most common in

60s

Five-year survival

3 – 5%

(breast cancer: 90%)

Sen. John McCain
US politician

Matt Price
ABC journalist

Stan Zemanek
Media personality

Andrew Olle
ABC journalist

Chris O'Brien, AO
Surgeon

KAZIA THERAPEUTICS

Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases

Standard of Care ('Stupp Regimen')





~35% of patients respond to temozolomide

Extends overall survival from 15 to 22 months

~65% of patients don't respond to temozolomide

Extends overall survival from 12 to 13 months

GDC-0084 is being developed for the ~65% of newly-diagnosed GBM patients who will not respond to existing chemotherapy with temozolomide

For these patients, there is no effective pharmacological treatment currently available

Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). *N Engl J Med* 352:997-1003

Note: Temozolomide is only approved therapy for newly-diagnosed patients; Avastin (bevacizumab) is approved for use in recurrent setting

KAZIA THERAPEUTICS

PI3K class is well-validated, but GDC-0084 is unique in its ability to cross the blood-brain barrier

	Zydelig (idelalisib)	Aliqopa (copanlisib)	Copiktra (duvelisib)	Piqray (alpelisib)	**GDC-0084**
					
	FDA Approved **July 2014** (blood cancers) [accelerated approval] ✓	FDA Approved **September 2017** (blood cancers) [accelerated approval] ✓	FDA Approved **October 2018** (blood cancers) [accelerated approval] ✓	FDA Approved **May 2019** (breast cancer) [accelerated approval] ✓	In phase II human trials under US FDA oversight (brain cancer)
	Does not cross blood-brain barrier ✗	Does not cross blood-brain barrier ✗	Does not cross blood-brain barrier ✗	Does not cross blood-brain barrier ✗	Does cross blood-brain barrier ✓
	Potentially fatal liver toxicity and diarrhoea ✗	Potentially fatal infections ✗	Potentially fatal infections & diarrhoea ✗	Limited toxicities to date ✓	Appears generally safe and well-tolerated thus far ✓

In GDC-0084 phase 1, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET

Pre-Dosing *On GDC-0084* *Pre-Dosing* *On GDC-0084*



Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory

In an ongoing phase II study, GDC-0084 shows evidence of delaying tumour progression

Progression-Free Survival (PFS)



Overall Survival (OS)



Note: figures for existing therapy are for temozolomide, per Hegi et al. (2005); comparison between different studies is never perfectly like-for-like

KAZIA THERAPEUTICS

Brain cancer represents a significant commercial opportunity for GDC-0084, with limited competition

Path to Market

Glioblastoma

12,500

patients p.a. in the US

~$1.5B+

market opportunity

Expansion Opportunities

Brain Metastases (secondary brain cancer)

Other Adult Primary Brain Cancers

Childhood Brain Cancers

‘Blue Sky’ Potential

Other Cancers with Disordered PI3K Pathway

(*e.g. breast, lung, blood*)

Recent institutional placement leaves the company well funded for next round of data read-outs

Market Capitalisation	~AU$ 45 million
Listing	NASDAQ: KZIA (1:10 ratio) ASX: KZA

Successful placement in October 2019

Current Assets (30 June 2019) — $7.5 million

\+

Institutional Placement (October 2019) — $4.0 million

↓

Funded for multiple value-driving data readouts during 4Q 2019 and 1H 2020

KAZIA THERAPEUTICS

The partnering market for new oncology drugs is active and driven by emerging data

Select CY2019 Licensing Transactions

Licensee	Licensor	Stage	Asset(s)	Deal Value (US$)
GILEAD	CARNA BIOSCIENCES	Discovery	Lipid kinase inhibitors	$470M
Johnson & Johnson	Genmab	Preclinical	Anti-CD38 antibody	$275M
Jazz Pharmaceuticals	Redx Pharma	Preclinical	RAS-RAF-MAPK inhibitors	$207M
Boehringer Ingelheim	LUPIN	Clinical	MEK inhibitor	$700M
Mallinckrodt Pharmaceuticals	SILENCE THERAPEUTICS	Discovery	Complement modulator	$2.0B

Select CY2019 M&A Transactions

Acquirer	Target	Stage	Asset(s)	Deal Value (US$)
Pfizer	ARRAY BIOPHARMA	Commercial	BRAF inhibitors	$11.0B
MERCK	Peloton Therapeutics	Clinical	HIF-2α inhibitors	$2.2B
AMGEN	NUEVOLUTION	Discovery	Discovery platform	$167M
Boehringer Ingelheim	AMAL Therapeutics	Clinical	Cancer vaccine platform	$367M

The next six months will be an exciting period for Kazia, and a crucial inflection point for our programs

November 2019	Initial interim data from ongoing phase 2 study of paxalisib in glioblastoma
December 2019	Extraordinary General Meeting (EGM) of shareholders
February 2020	Half-Year Report
1Q CY2020	Completion of patient dosing in Cantrixil phase 1 study
1Q CY2020	Announcement of phase 3 strategy for paxalisib
2Q CY2020	Potential initial efficacy data from St Jude paxalisib DIPG study
2Q CY2020	Potential initial efficacy data from Dana-Farber paxalisib breast cancer mets study
2Q CY2020	Further efficacy data from ongoing phase 2 study of paxalisib in glioblastoma

Note: all milestones are indicative and subject to periodic revision in light of operational factors and emerging data

Investment Rationale

1. Our lead program, GDC-0084, was **designed by Genentech**, and is being developed for glioblastoma, the most common form of brain cancer, where the only available drug is ineffective for two-thirds of patients

2. GDC-0084 has shown strong evidence of efficacy in an ongoing phase II human trial in the United States; a pivotal study for registration is planned to commence in CY 2020

3. **Four other clinical trials** of GDC-0084 are currently underway at leading US hospitals, all primarily funded by external parties, covering a broad range of primary and secondary brain cancers to provide **multiple shots on goal**

4. Company is **well-financed**, following a recent institutional placement, with multiple value-driving data read-outs expected during the early part of CY 2020 and high potential to partner with big pharma

www.kaziatherapeutics.com